VANCOUVER, British Columbia, July 06, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the "Company" or "Grey Matters") (CSE: GREY) (FRANKFURT: AGW0) (OTC: AGNPF), a Canadian healthcare company, is pleased to announce that it has taken delivery of its first brain dedicated PET (Positron Emission Tomography) scanning system for its flagship NovaScan Neuroimaging ClinicsTM location, opening soon in Davie, Florida.
The clinic will be the first of its kind in the U.S. to offer brain only PET scanning to assist in meeting the growing demand for early Alzheimer's detection through beta-amyloid imaging, and to provide a key diagnostic imaging tool for other neurodegenerative diseases as well.
The clinic will feature the U.S. FDA-cleared CareMiBrain™ system, a ground-breaking, new streamlined PET scanner, that does not need an integrated Computed Tomography (CT) component to produce high quality images, resulting in 25% less radiation exposure for patients and a comfortable chair styled design. Brain PET scans for beta-amyloid plaque detection associated with advancing Alzheimer's (AD) are covered by Medicare, Medicaid, and private insurance for patients 65+.
"Taking delivery of our first brain dedicated PET scanner is a tremendous milestone for the company," said Christopher J. Moreau, CEO of Grey Matters Health. "We look forward to launching our flagship location in Florida, which will be the first of many neuroimaging clinics we plan to open across the U.S. featuring this revolutionary new technology. Each clinic will offer the highest level of care possible to our patients, providing an improved diagnostic imaging experience that will reduce patient claustrophobia and dizziness through sitting instead of lying prone, with added radiology reporting features and advantages for referring physicians as well."
The inaugural clinic will be located at the HCA Florida University Medical Office Building, on the HCA Florida University Hospital campus. It will be the first such clinic in the U.S. to provide brain dedicated PET scans to aid the medical community in the diagnosis of AD.
Click here for a 3D Tour of the soon to be completed space: Offices 360 View
The CareMiBrain PET Brain Scanning System will also be utilized in the clinic to conduct imaging related to other neurodegenerative diseases as well, including frontotemporal dementia, Parkinson's, and Lewy Body Dementia, and will be additionally utilized for select neuro-oncology applications.
The U.S. FDA has recently approved two new monoclonal antibody treatments for AD, which are also covered by Medicare, Medicaid and private insurance, designed to slow the progression of the disease by dissolving beta-amyloid plaque in the brain – Leqembi (Eisai and Biogen) and Kisunla (Eli Lilly) - and both require a positive beta-amyloid brain scan (or spinal tap) in order for patients to be authorized to receive them. These drugs have helped create a billion-dollar market opportunity for the brain specific PET scan and AD treatment space and patients receiving treatment also require additional brain PET scans to monitor their progress.